Jul 26, 2019   SOURCE: PR NewsWire

China Biologic Products to Report Second Quarter 2019 Financial Results

BEIJING, July 26, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release its second quarter 2019 financial results on Monday, August 5, 2019 after the market closes.

The Company's management will hold a conference call at 7:30 a.m. ET on Tuesday, August 6, 2019, which is 7:30 p.m. Beijing Time on August 6, 2019, to discuss second quarter 2019 results. Listeners may access the call by dialing:


            US:                                   1 888 346 8982



            International:                        1 412 902 4272



            Hong Kong:                       
            800 905945



            China:                          
            4001 201203

A telephone replay will be available one hour after the conclusion of the conference call through August 13, 2019. The dial-in details are:


              US:                        
              1 877 344 7529



              International:             
              1 412 317 0088



              Passcode:                                   10133955

A live and archived webcast of the conference call will be available through the Company's investor relations website at http://chinabiologic.investorroom.com/.

About China Biologic Products Holdings, Inc.

China Biologic Products Holdings, Inc. (NASDAQ: CBPO) is a leading fully integrated plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosage forms of plasma products through its indirect majority-owned subsidiary, Shandong Taibang Biological Products Co., Ltd. and its wholly owned subsidiary, Guizhou Taibang Biological Products Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. Since the acquisition of TianXinFu (Beijing) Medical Appliance Co., Ltd. in 2018, China Biologic is also engaged in the manufacturing and sale of medical devices, primarily regenerative medical biomaterial products. The Company sells its products to hospitals, distributors and other healthcare facilities in China. For additional information, please see the Company's website www.chinabiologic.com.

Contact:

China Biologic Products Holdings, Inc.
Mr. Ming Yin
Senior Vice President
Email: ir@chinabiologic.com

The Foote Group
Mr. Philip Lisio
Phone: +86-135-0116-6560
E-mail: phil@thefootegroup.com

View original content:http://www.prnewswire.com/news-releases/china-biologic-products-to-report-second-quarter-2019-financial-results-300891586.html

SOURCE China Biologic Products Holdings, Inc.